Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria

Background. Although the association between lipoatrophy and highly active antiretroviral therapy (HAART) is well known, other nondrug factors may be associated with lipoatrophy in people living with HIV/AIDS (PLWHA). There are no reports of lipoatrophy from Nigeria, a country with the second larges...

Full description

Saved in:
Bibliographic Details
Main Authors: Sandra Omozehio Iwuala, Olufunmilayo A. Lesi, Olufemi Adetola Fasanmade, Anas A. Sabir, Michael Adeyemi Olamoyegun, Charles C. Okany
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:AIDS Research and Treatment
Online Access:http://dx.doi.org/10.1155/2015/402638
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850167673858555904
author Sandra Omozehio Iwuala
Olufunmilayo A. Lesi
Olufemi Adetola Fasanmade
Anas A. Sabir
Michael Adeyemi Olamoyegun
Charles C. Okany
author_facet Sandra Omozehio Iwuala
Olufunmilayo A. Lesi
Olufemi Adetola Fasanmade
Anas A. Sabir
Michael Adeyemi Olamoyegun
Charles C. Okany
author_sort Sandra Omozehio Iwuala
collection DOAJ
description Background. Although the association between lipoatrophy and highly active antiretroviral therapy (HAART) is well known, other nondrug factors may be associated with lipoatrophy in people living with HIV/AIDS (PLWHA). There are no reports of lipoatrophy from Nigeria, a country with the second largest number of PLWHA. We aimed to determine the prevalence, characteristics, and factors associated with lipoatrophy in a cohort of patients attending the HIV clinic in Lagos University Teaching Hospital, Nigeria. Methods. Two hundred and eighty-eight patients with HIV infection were recruited for the study. The study protocol involved administration of a questionnaire, targeted physical examination (including anthropometric indices and skin fold thickness), and bioelectrical impedance analysis measurements. Lipoatrophy was defined clinically. Results. Lipoatrophy was present in 75 (26.0%) persons. It was associated with lower body circumferences, skin fold thicknesses, and lower % body fat with preservation of skeletal muscle mass (all P<0.05). Male gender and HAART use were the factors associated with lipoatrophy on multivariate analysis (P<0.05). Conclusion. Lipoatrophy is frequently encountered in patients with HIV infection in Nigeria, with HAART use conferring an added factor in its development. There is need for more physician and patient awareness of this condition.
format Article
id doaj-art-e750a511c21249328febe2dfafe9149e
institution OA Journals
issn 2090-1240
2090-1259
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series AIDS Research and Treatment
spelling doaj-art-e750a511c21249328febe2dfafe9149e2025-08-20T02:21:09ZengWileyAIDS Research and Treatment2090-12402090-12592015-01-01201510.1155/2015/402638402638Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in NigeriaSandra Omozehio Iwuala0Olufunmilayo A. Lesi1Olufemi Adetola Fasanmade2Anas A. Sabir3Michael Adeyemi Olamoyegun4Charles C. Okany5Department of Medicine, College of Medicine University of Lagos, PMB 12003, Lagos, NigeriaDepartment of Medicine, College of Medicine University of Lagos, PMB 12003, Lagos, NigeriaDepartment of Medicine, College of Medicine University of Lagos, PMB 12003, Lagos, NigeriaDepartment of Medicine, Usmanu Danfodiyo University Teaching Hospital, PMB 2370, Sokoto, NigeriaDepartment of Medicine, LAUTECH Teaching Hospital and College of Health Sciences, Ladoke Akintola University of Technology, PMB 4007, Ogbomoso, Oyo State, NigeriaDepartment of Haematology and Blood Transfusion, Lagos University Teaching Hospital, PMB 12003, Lagos, NigeriaBackground. Although the association between lipoatrophy and highly active antiretroviral therapy (HAART) is well known, other nondrug factors may be associated with lipoatrophy in people living with HIV/AIDS (PLWHA). There are no reports of lipoatrophy from Nigeria, a country with the second largest number of PLWHA. We aimed to determine the prevalence, characteristics, and factors associated with lipoatrophy in a cohort of patients attending the HIV clinic in Lagos University Teaching Hospital, Nigeria. Methods. Two hundred and eighty-eight patients with HIV infection were recruited for the study. The study protocol involved administration of a questionnaire, targeted physical examination (including anthropometric indices and skin fold thickness), and bioelectrical impedance analysis measurements. Lipoatrophy was defined clinically. Results. Lipoatrophy was present in 75 (26.0%) persons. It was associated with lower body circumferences, skin fold thicknesses, and lower % body fat with preservation of skeletal muscle mass (all P<0.05). Male gender and HAART use were the factors associated with lipoatrophy on multivariate analysis (P<0.05). Conclusion. Lipoatrophy is frequently encountered in patients with HIV infection in Nigeria, with HAART use conferring an added factor in its development. There is need for more physician and patient awareness of this condition.http://dx.doi.org/10.1155/2015/402638
spellingShingle Sandra Omozehio Iwuala
Olufunmilayo A. Lesi
Olufemi Adetola Fasanmade
Anas A. Sabir
Michael Adeyemi Olamoyegun
Charles C. Okany
Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria
AIDS Research and Treatment
title Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria
title_full Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria
title_fullStr Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria
title_full_unstemmed Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria
title_short Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria
title_sort prevalence of and risk factors for lipoatrophy in patients with hiv infection in nigeria
url http://dx.doi.org/10.1155/2015/402638
work_keys_str_mv AT sandraomozehioiwuala prevalenceofandriskfactorsforlipoatrophyinpatientswithhivinfectioninnigeria
AT olufunmilayoalesi prevalenceofandriskfactorsforlipoatrophyinpatientswithhivinfectioninnigeria
AT olufemiadetolafasanmade prevalenceofandriskfactorsforlipoatrophyinpatientswithhivinfectioninnigeria
AT anasasabir prevalenceofandriskfactorsforlipoatrophyinpatientswithhivinfectioninnigeria
AT michaeladeyemiolamoyegun prevalenceofandriskfactorsforlipoatrophyinpatientswithhivinfectioninnigeria
AT charlescokany prevalenceofandriskfactorsforlipoatrophyinpatientswithhivinfectioninnigeria